TO ALL:
Subj: TSE Listing Granted
Date: 3/15/99 2:39:47 PM Eastern Standard Time
From: lplourde@gensci-regen.com (Louis G. Plourde)
To: lgplourde@sympatico.ca
GenSci Regeneration Sciences Inc.
201 - 5090 Explorer Drive
Mississauga, ON
L4W 4T9 Canada
Tel (905) 629-7557
Fax (905) 629-4648
March 15, 1999
Trading Symbol: GNS.V
GENSCI LISTS ON TSE
Toronto, Ontario, March 15, 1999 GenSci Regeneration Sciences Inc. today
announced that The Toronto Stock Exchange has approved the Company's
application for listing. GenSci's shares will begin trading March 16, 1999
under the symbol “GNS”.
“The move to a senior exchange is an important step in GenSci's growth,” said
Dr. James Trotman, President and Chief Executive Officer. “Since our initial
listing on the Vancouver Stock Exchange in 1992, GenSci has made significant
strides in all areas. We strengthened our scientific foundation by licensing
key technologies and ramping up R&D; we enhanced our management team with
several significant appointments; and we successfully introduced our initial
product line to the spinal surgical market, achieving $16 million in sales in
1998, the first full year of the products' availability.
“With our growing profile in the medical community, it also is important for us
to increase GenSci's presence in the North American investment community. This
begins with listing our shares on the TSE, the most prestigious exchange in
Canada,” he continued.
GenSci Regeneration Sciences Inc. is a Canadian public company dedicated to the
research and development of innovative technologies for bone and tissue
regeneration and repair. The company is currently producing and marketing a
proprietary line of bioimplant products for surgical applications at its
Irvine, California manufacturing facility. The company's head office and
research facilities are located in the greater Toronto area.
Certain statements contained herein constitute forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995.
Such forward-looking statements involve known and unknown risks, uncertainties,
and other factors, which may cause the actual results, performance or
achievements of the company to be materially different from those expressed or
implied. Forward-looking statements involve risks and uncertainties,
including, but not limited to, such risks as are described in the company's
annual report.
For more information contact:
Dr. James Trotman
Chairman, CEO, and President
(800) 561-2955 / (905) 629-7557
Web Site: www.gensci.bc.ca
The Vancouver Stock Exchange has not reviewed and does not accept
responsibility for the adequacy or accuracy of this release.
--------------------
GenSci Regeneration
Sciences Inc.
<div align="right">201 - 5090 Explorer Drive
Mississauga, ON
L4W 4T9 Canada
Tel (905) 629-7557
Fax (905) 629-4648
</div>March 15,1999<x-tab> </x-tab><x-tab> </x-tab><x-tab> </x-tab><x-tab> </x-tab><x-tab> </x-tab> <x-tab> </x-tab><x-tab> </x-tab> <x-tab> </x-tab>
Trading Symbol: GNS.V
<div align="center">GENSCI LISTS ON TSE
</div>Toronto, Ontario, March 15, 1999 GenSci Regeneration Sciences Inc. today announced that The Toronto Stock Exchange has approved the Company's application for listing. GenSci's shares will begin trading March 16, 1999 under the symbol “GNS”.
“The move to a senior exchange is an important step in GenSci's growth,” said Dr. James Trotman, President and Chief Executive Officer. “Since our initial listing on the Vancouver Stock Exchange in 1992, GenSci has made significant strides in all areas. We strengthened our scientific foundation by licensing key technologies and ramping up R&D; we enhanced our management team with several significant appointments; and we successfully introduced our initial product line to the spinal surgical market, achieving $16 million in sales in 1998, thefirst full year of the products' availability.
“With our growing profile in the medical community, it also is important for us to increase GenSci's presence in the North American investment community. This begins with listing our shares on the TSE, the most prestigious exchange in Canada,” he continued.
GenSci Regeneration Sciences Inc. is a Canadian public company dedicatedto the research and development of innovative technologies for bone and tissue regeneration and repair. The company is currently producing and marketing a proprietary line of bioimplant products for surgical applications at its Irvine, California manufacturing facility. The company's head office and research facilities are located in the greaterToronto area.
Certain statements contained herein constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties, and other factors, which may cause the actual results, performance or achievements of the company to be materially different from those expressed or implied. Forward-looking
statements involve risks and uncertainties, including, but not limitedto, such risks as are described in the company's annual report.
For more information contact:
Dr. James Trotman
Chairman, CEO, and President
(800) 561-2955 / (905) 629-7557
Web Site: www.gensci.bc.ca
The Vancouver Stock Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.
----------------------- Headers --------------------------------
Return-Path: <lplourde@gensci-regen.com>
Received: from rly-za04.mx.aol.com (rly-za04.mail.aol.com [172.31.36.100]) by air-za03.mail.aol.com (v56.26) with SMTP; Mon, 15 Mar 1999 14:39:47 1900
Received: from smtp13.bellglobal.com (smtp13.bellglobal.com [204.101.251.52])
by rly-za04.mx.aol.com (8.8.8/8.8.5/AOL-4.0.0)
with ESMTP id OAA23826;
Mon, 15 Mar 1999 14:39:33 -0500 (EST)
Received: from mrelay ([192.168.1.119])
by smtp13.bellglobal.com (8.8.5/8.8.5) with ESMTP id OAA17032;
Mon, 15 Mar 1999 14:39:36 -0500 (EST)
Received: from lotuis.bellglobal.com by mrelay.bellglobal.com
(PMDF V5.1-12 #26722) with SMTP id <0F8N00H7NIABV7@mrelay.bellglobal.com>;
Mon, 15 Mar 1999 14:35:49 -0500 (EST)
Date: Mon, 15 Mar 1999 14:30:26 -0500
From: "Louis G. Plourde" <lplourde@gensci-regen.com>
Subject: TSE Listing Granted
X-Sender: lplourde@mail3.bellglobal.com
To: lgplourde@sympatico.ca
Message-id: <4.1.19990315142958.009957b0@mail3.bellglobal.com>
MIME-version: 1.0
X-Mailer: QUALCOMM Windows Eudora Pro Version 4.1
Content-type: MULTIPART/ALTERNATIVE;
BOUNDARY="Boundary_(ID_pHZdGNdbhYoYmdeNAUutkw)" |
